

care (L Ridsdale et al, personal communication) are due to report shortly.

Option: Oral nicotinamide adenine dinucleotide

One small RCT found evidence of limited benefit from oral nicotinamide adenine dinucleotide.

Benefits

We found no systematic review. We found one RCT using a crossover design, which compared nicotinamide adenine dinucleotide (NADH) 10 mg a day and placebo over four weeks.⁴⁰ Of the 33 people with chronic fatigue syndrome who completed the study, 26 were included in the analysis. On a symptom rating scale, 8/26 receiving the study drug attained a 10% improvement, compared with 2/26 receiving placebo.

Harms

Minor adverse effects (loss of appetite, dyspepsia, flatulence) were reported with the study drug but did not lead to stopping treatment.

Comment

The rationale for this treatment is that NADH facilitates generation of ATP, which may be depleted in chronic fatigue syndrome.⁴⁰ The authors plan to conduct a further study using greater numbers.

We thank *Clinical Evidence* musculoskeletal disorders advisers: Troels Mork Hansen, Herlev, Denmark, and John Stothard, Middlesbrough, UK.

Competing interests: None declared.

- Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins J, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. *Ann Intern Med* 1994;121:953-9.
- Sharpe M, Archard LC, Banaivala JE. A report—chronic fatigue syndrome: guidelines for research. *J R Soc Med* 1991;84:118-21.
- Wessely S, Chalder T, Hirsch S, Wallace P, Wright D. The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primary care study. *Am J Public Health* 1997;87:1449-55.
- Steele L, Dobbins JG, Fukuda K, Reyes M, Randall B, Koppelman M, et al. The epidemiology of chronic fatigue in San Francisco. *Am J Med* 1998;105(suppl 3A):83-90S.
- Lawrie SM, Pelosi AJ. Chronic fatigue syndrome in the community: prevalence and associations. *Br J Psychiatry* 1995;166:793-7.
- Wessely S. The epidemiology of chronic fatigue syndrome. *Epidemiological Reviews* 1995;17:1-13.
- Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. *Q J Med* 1997;90:223-33.
- Stewart AD, Hays RD, Ware JE. The MOS short-form general health survey. *Medical Care* 1988;26:724-32.
- Karnofsky DA, Burchenal JH, MacLeod CM, eds. *The clinical evaluation of chemotherapeutic agents in cancer*. New York: Columbia University Press, 1949:191-206.
- Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh JK. An inventory for measuring depression. *Arch Gen Psych* 1961;4:561-71.
- Bergner M, Bobbit RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. *Medical Care* 1981;19:787-805.
- Vercoulen J, Swanink C, Zitman F. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. *Lancet* 1996;347:858-61.
- Wearden AJ, Morriss RK, Mullis R, Strickland PL, Pearson DJ, Appleby L, et al. Randomised, double-blind, placebo controlled treatment trial of fluoxetine and a graded exercise programme for chronic fatigue syndrome. *Br J Psychiatry* 1998;172:485-90.
- Natelson BH, Cheu J, Pareja J, Ellis SP, Poliscastro T, Findley TW. Randomised, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. *Psychopharmacology* 1996;124:226-30.
- Behan PO, Hannifan H. 5-HT reuptake inhibitors in CFS. *J Immunol Immunopharmacology* 1995;15:66-9.
- Peterson PK, Pheley A, Schroepel J, Schenck C, Marshall P, Kind A, et al. A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome. *Arch Intern Med* 1998;158:908-14.
- McKenzie R, O'Fallon A, Dale J, Demitrack M, Sharma G, Deloria M, et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome. *JAMA* 1998;280:1061-6.
- Clare AJ, Heap E, Malhi G, Wessely S, O'Keane V, Miell J. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. *Lancet* 1999;353:455-8.
- Bou-Holaigh I, Rowe P, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. *JAMA* 1995;274:961-7.

Clinical Evidence is published by BMJ Publishing Group and American College of Physicians-American Society of Internal Medicine. The first issue is available now, and *Clinical Evidence* will be updated and expanded every six months. Individual subscription rate, issues 2 and 3, £55/\$115; institution rate £132/\$211. For more information including how to subscribe, please visit the *Clinical Evidence* website at www.evidence.org

- Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. *J Clin Endocrinol Metab* 1991;73:1224-34.
- Fulcher KY, White PD. A randomised controlled trial of graded exercise therapy in patients with the chronic fatigue syndrome. *BMJ* 1997;314:1647-52.
- Sandler H, Vernikos J. *Inactivity: physiological effects*. London: Academic Press, 1986.
- Dalrymple W. Infectious mononucleosis: 2. Relation of bed rest and activity to prognosis. *Postgrad Med* 1961;35:345-9.
- Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. *Lancet* 1991;337:757-60.
- Behan PO, Behan WMH, Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. *Acta Neurol Scand* 1990;82:209-16.
- Warren G, McKendrick M, Peet M. The role of essential fatty acids in chronic fatigue syndrome. *Acta Neurol Scand* 1999;99:112-6.
- Clague JE, Edwards RHT, Jackson MJ. Intravenous magnesium loading in chronic fatigue syndrome. *Lancet* 1992;340:124-5.
- Hinds G, Bell NP, McMaster D, McCluskey DR. Normal red cell magnesium concentrations and magnesium loading tests in patients with chronic fatigue syndrome. *Ann Clin Biochem* 1994;31:459-61.
- Swanink CM, Vercoulen JH, Bleijenberg G, Fennis JF, Galama JM, van der Meer JW. Chronic fatigue syndrome: a clinical and laboratory study with a well matched control group. *J Intern Med* 1995;237:499-506.
- Peterson PK, Shepard J, Macres M, Schenck C, Crosson J, Rechtman D, et al. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. *Am J Med* 1990;89:554-60.
- Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. *Am J Med* 1990;89:561-8.
- Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, Tymms K, Wakefield D, Dwyer J, et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. *Am J Med* 1997;103:38-43.
- Rowe KS. Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents. *J Psychiatr Res* 1997;31:133-47.
- See DM, Tilles JG. Alpha interferon treatment of patients with chronic fatigue syndrome. *Immunological Investigations* 1996;25:153-64.
- Lloyd A, Hickie I, Brockman A, Hickie C, Wilson A, Dwyer J, et al. Immunologic and psychological therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. *Am J Med* 1993;94:197-203.
- Steinberg P, McNutt BE, Marshall P, Schenck C, Lurie N, Pheley A, et al. Double-blind placebo-controlled study of efficacy of oral terfenadine in the treatment of chronic fatigue syndrome. *J Allergy Clin Immunol* 1996;97:119-26.
- Price JR, Couper J. Cognitive behaviour therapy for CFS. In: Cochrane Collaboration. *Cochrane Library*. Issue 4. Oxford: Update Software, 1998.
- Sharpe M, Hawton K, Simkin S, Surawy C, Hackmann A, Klimes I, et al. Cognitive behaviour therapy for chronic fatigue syndrome: a randomised controlled trial. *BMJ* 1996;312:22-6.
- Deale A, Chalder T, Marks I, Wessely S. Cognitive behaviour therapy for chronic fatigue syndrome: a randomized controlled trial. *Am J Psychiatry* 1997;154:408-14.
- Forsyth LM, Preuss HG, MacDowell AL, Chiazzie L Jr, Birkmayer GD, Bellanti JA. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. *Ann Allergy Asthma Immunol* 1999;82:185-91.

Corrections and clarifications

ABC of complementary medicine:

Unconventional approaches to nutritional medicine

In this article by Andrew Vickers and Catherine Zollman (27 November, pp 1419-22) the box "Examples of dietary interventions claimed to help in specific conditions" (p 1420) should have stated that the Gerson diet for cancer consisted of a vegetarian diet with "coffee enemas and various supplements" (not "coffee, enemas, and various supplements").

National electronic Library for Health (NeLH)

In this article by J A Muir Gray and Simon de Lusignan (4 December, pp 1476-9) Sir Edward Wayne's name was misspelt (p 1476).

Obituaries

In the obituary of Dr Douglas Arthur Longmore Ashforth (4 December 1999, p 1503), Dr Ashforth's surname was misspelt.

Reviews

In Stuart Brooks's review of the CD Rom *The Virtual Surgeon: ACL Reconstruction* (27 November, p 1442), the price quoted for the CD was £363. In fact, it is available for £150 from TVF Multimedia (tel 020 7837 3000).